The CDC recommends that all sexually active adolescent women be screened for chlamydia trachomatis at least once a year. Close to half of chlamydia cases (46%) occur in women ages 15-19 and another 33% of infections occur in females between 20 and 24. Of all reported neisseria gonorrhoeae cases, 75% occur in individuals between 15 and 29 years of age.
Transcription-Mediated Amplification (TMA)
3.0 mL ThinPrep® PAP or SurePath™ Test Pack
1.0 mL liquid cytology media (ThinPrep or SurePath) media
One cervical or urethral swab collected with APTIMA Unisex Swab Specimen Collection (WHITE) Kit
20.0-30.0 mL (first catch) urine collected in preservative-free urine collection cup or 2.0 mL urine transferred to APTIMA urine specimen transport (YELLOW) tube
Transport and store all specimens at 2-30°C
Insufficient specimen volume
No swab in transport tube
Urine specimens >24 hours old unless transferred to APTIMA urine transport (YELLOW) tube
Intended for use as a screening test for evidence of Chlamydia trachomatis infection.
APTIMA Combo 2 is a trademark of Gen-Probe, Inc.
ThinPrep is a registered trademark of Cytyc Corporation.
SurePath is a trademark of Becton, Dickinson and Company.